--- title: "11:30 ETAvirmax Biopharma Inc. Proudly Presents at the 2026 ARVO Annual Meeting in Denver, Colorado" type: "News" locale: "en" url: "https://longbridge.com/en/news/284243035.md" description: "Avirmax Biopharma Inc. will present two scientific papers at the 2026 ARVO Annual Meeting in Denver, Colorado, from May 3-7, 2026. The presentations will focus on advancements in ocular genetic medicine, including the development of gene therapy for ocular disorders. Dr. Sameera Peraramelli will discuss the integration of ddPCR and protein quantification for AAV-specific vector genome determination, while Dr. Shengjiang Liu will present on the preclinical development of ABI-110 gene therapy. Avirmax will also exhibit at Booth #5028 to showcase its latest advancements." datetime: "2026-04-27T15:30:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284243035.md) - [en](https://longbridge.com/en/news/284243035.md) - [zh-HK](https://longbridge.com/zh-HK/news/284243035.md) --- # 11:30 ETAvirmax Biopharma Inc. Proudly Presents at the 2026 ARVO Annual Meeting in Denver, Colorado , /PRNewswire/ -- Avirmax Inc. will deliver two scientific presentations at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Denver, Colorado May 3 - 7, 2026. ARVO is the largest international society dedicated to ophthalmology and related visual sciences. Title: **Analytical Integration of ddPCR and Protein Quantification Enhances Accuracy of AAV-Specific Vector Genome Determination** Presenter: Sameera Peraramelli, Ph.D. Session Title: Gene Editing and Gene Therapy II Session Date/Time: May 5, 2026, from 8:30 AM to 10:15 AM MDT Dr. Shengjiang Liu, Ph.D. Chief Executive and Scientific Officer will present "**From Bench to Clinic: CMC and Preclinical Development of ABI-110 Gene Therapy for Ocular Neovascularized Disorders**", Poster-Board Number: 3655 – 0748, Session Number: 371, Session Title: AMD: Translational studies, Session Date/Times: May 5, 2026, from 3:30 PM to 5:15 PM. These presentations will highlight the company's continued commitment to advancing ocular genetic medicine programs, including the development of its proprietary macular targeting capsid AAV.N54, vector manufacturing, testing & quality control, while also highlighting the importance of precise vector genome titer determination to enable accurate dose delivery in clinical trials, alongside the application of robust nonclinical models for treating wet AMD, including PCV. Furthermore, Avirmax Biopharma will exhibit at Booth #5028 to showcase its latest advancements and comprehensive data packages. **About Avirmax Inc.** Avirmax Biopharma Inc. is a San Francisco-based company that specializes in developing rAAV-mediated therapeutics for ocular diseases using its AAV engineering technologies and Sf9-based AAV manufacturing platform. Since its inception, Avirmax Biopharma has been dedicated to developing safe, effective, and widely available AAV gene therapy products to meet the unmet needs of patients. Please visit avirmax.com for more information. **Contact** June Song, Director of Operations \[email protected\] +1-510-641-0201 25503 Whitesell Street, Hayward, CA 94545, USA SOURCE Avirmax ### Related Stocks - [ABVC.US](https://longbridge.com/en/quote/ABVC.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) ## Related News & Research - [Cardiff Oncology updates Phase 2 onvansertib data in first-line RAS-mutated mCRC trial](https://longbridge.com/en/news/287272648.md) - [Nuvalent to present pivotal ALKOVE-1 neladalkib data in ALK-positive NSCLC at ASCO 2026](https://longbridge.com/en/news/287275055.md) - [Black Diamond reports Phase 2 silevertinib mPFS 15.2 months in frontline EGFR-mutant NSCLC](https://longbridge.com/en/news/287274011.md) - [Kite presents updated Phase 1 data for KITE-753 CAR-T in relapsed B-cell lymphoma](https://longbridge.com/en/news/287273996.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)